Karyopharm Therapeutics Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a KPTI research report →
Range $3 – $16
Price Chart
About the company
Karyopharm Therapeutics Inc. is a pharmaceutical company that has already brought products to market, focusing on identifying, advancing, and selling medications designed to disrupt nuclear export pathways. These drugs are primarily aimed at treating cancer and various other illnesses.
- CEO
- Richard A. Paulson
- IPO
- 2013
- Employees
- 228
- HQ
- Newton, MA, US
Get TickerSpark's AI analysis on KPTI
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
Latest fiscal year · YoY change
- Revenue
- $146.07M+0.6%
- Gross Profit
- $140.12M+0.6%
- Op Income
- $-90,707,000
- Net Income
- $-196,039,000-156.5%
- EPS
- $-17.93-90.5%
- OCF Growth
- +40.9%
- FCF Growth
- +40.9%
- 52W High
- $10.99
- 52W Low
- $0.01
- 50D MA
- $0.92
- 200D MA
- $5.78
- Beta
- 1.04
- RSI (14)
- 29
- Avg Volume
- 8.63M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Karyopharm said it remains on track to file its myelofibrosis sNDA in August, but the quarter was also marked by soft revenue, a larger net loss, and an urgent need to address near-term financing.· August 13, 2026
- sNDA for selinexor in myelofibrosis is still planned for August, with FDA discussions described as constructive.
- Management said the submission will rely on the week 24 SENTRY data and includes the pre-specified overall survival analysis, with additional OS follow-up to serve as confirmatory data later.
- XPOVIO U.S. net product revenue was $30.8 million, while total revenue declined to $33.4 million from $37.9 million a year ago because Menarini reimbursement ended.
- The company ended Q2 with $65.4 million in cash, cash equivalents, restricted cash, and investments and said liquidity funds current plans into September 2026.
- Management is evaluating financing opportunities and strategic alternatives as a $15.8 million term-loan principal payment is due on September 10, 2026.
Total revenue was $33.4 million in the second quarter of 2026 versus $37.9 million in the prior-year period. U.S. XPOVIO net product revenue was $30.8 million versus $29.7 million a year ago, and the gross-to-net rate was 26.6%, comparable to Q2 2025. R&D expense was $29 million, down 12% year over year, and SG&A was $25.9 million, down 9% year over year. Net loss was $67 million versus $37.3 million in the prior-year quarter, with management noting the underlying loss from operations improved by approximately 8%. The company ended the quarter with $65.4 million in cash, cash equivalents, restricted cash, and investments. For 2026, management reaffirmed total revenue of $130 million to $150 million, U.S. XPOVIO net product revenue of $115 million to $130 million, and combined R&D plus SG&A of $230 million to $245 million, excluding certain one-time costs tied to endometrial cancer and financing/strategic transactions. Management said existing liquidity plus expected product and license revenue should fund current plans into September 2026.
Richard Paulson framed the quarter as the start of an important new chapter, centered on advancing selinexor in myelofibrosis through the FDA pathway. He emphasized the strength of the SENTRY data, the planned August sNDA submission, and the company’s belief that selinexor plus ruxolitinib could become the first approved combination therapy in myelofibrosis. He also said the company is deliberately narrowing its focus to hematology and is reducing planned investment in endometrial cancer. His tone was confident but urgent, especially around execution and capital allocation.
Lori Macomber highlighted that total revenue fell to $33.4 million from $37.9 million largely because Menarini reimbursement of development expenses ended, which reduced revenue by about $6.5 million versus last year. She noted U.S. XPOVIO net product revenue of $30.8 million, steady underlying demand, and a 26.6% gross-to-net rate. R&D was $29 million and SG&A was $25.9 million, both down year over year, reflecting tighter spending and prioritization. She also said the company had $65.4 million in cash, cash equivalents, restricted cash, and investments, expects runway into September 2026, and faces a $15.8 million principal payment due September 10, 2026 that could create a covenant issue absent financing or a waiver.
Analysts focused heavily on what remains for the sNDA, whether accelerated approval is necessary, how much weight NCCN compendia could carry, and how the company plans to manage the September debt payment. Management said most of the sNDA is already assembled, that the submission will be based on week 24 data with the pre-specified OS analysis included, and that the confirmatory package will rely on mature OS follow-up from ongoing SENTRY. On regulatory timing, Reshma Rangwala said priority review is not something the FDA has previewed, while Richard Paulson said NCCN is important but not sufficient by itself and that the company is in productive talks with lenders on financing and waiver options.
The bullish case from the call is that Karyopharm believes it has a clear, near-term regulatory path for a potentially differentiated myelofibrosis therapy, backed by what it described as rapid, deep, sustained spleen responses and a promising OS signal. Management also said the company already has a hematology commercial infrastructure in place, which could support a rapid launch if approved. They pointed to continued physician interest, potential NCCN inclusion, and a market opportunity they described as up to approximately $1 billion in peak annual U.S. revenue.
The biggest risk is financial: Karyopharm said it has $65.4 million in liquidity, expects to fund current plans only into September 2026, and faces a $15.8 million term-loan payment on September 10 that could trigger default if not addressed. The endometrial cancer program also missed its primary endpoint, leading the company to reduce investment there. On top of that, the company still needs FDA acceptance and possible priority review on the myelofibrosis filing, and management acknowledged that approval timing and financing outcomes are still uncertain.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 65.4%
- Shares Outstanding
- 22.68M
- Float Shares
- 14.82M
of shares held by institutions
112 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Adage Capital Partners Gp, L.L.C. | 2.00M | ▲ 476.37K |
| Blackrock, Inc. | 1.52M | ▲ 103.12K |
| Acorn Capital Advisors, LLC | 1.22M | ▼ 296.09K |
| Catalio Capital Management, LP | 976.19K | ▲ 35.34K |
| Ubs Group AG | 963.89K | ▲ 610.35K |
| Vanguard Capital Management LLC | 940.81K | ▼ 18.17K |
| Aqr Capital Management LLC | 931.66K | ▲ 931.66K |
| Avidity Partners Management LP | 884.90K | ▼ 39.59K |
| Acadian Asset Management LLC | 617.90K | ▲ 318.91K |
| Vanguard Group Inc | 559.62K | ▲ 151.40K |
| Strs Ohio | 542.50K | ▲ 542.50K |
| Geode Capital Management, LLC | 458.52K | ▼ 72.71K |
Held by 37 ETFs
Biggest fund positions in KPTI by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 16, 26 | Abate Kristin | sell | 4,788 |
| Oct 1, 26 | Abate Kristin | sell | 378 |
| Sep 1, 26 | Abate Kristin | sell | 19 |
| Jul 28, 26 | Poulton Stuart | sell | 189 |
| May 21, 26 | Oliger Christy J. | other | 15,508 |
| May 21, 26 | PAKIANATHAN DEEPIKA | other | 15,508 |
| May 21, 26 | Schor Chen | other | 15,508 |
| May 21, 26 | Su Zhen | other | 15,508 |
| May 21, 26 | BOHLIN GAREN G | other | 15,508 |
| May 21, 26 | Greene Barry E | other | 15,508 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our KPTI coverage
Recent articles, reports, and earnings notes.
No research on KPTI yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate KPTI report →Karyopharm Announces FDA Acceptance of Supplemental New Drug Application for XPOVIO® (selinexor) Plus Ruxolitinib for the Treatment of Patients with Myelofibrosis
prnewswire.com · Nov 17
Karyopharm to Present Selinexor Data in Patients with Myelofibrosis and Multiple Myeloma at the 68th American Society of Hematology Annual Meeting and Exposition (ASH)
prnewswire.com · Nov 4
Karyopharm Therapeutics Inc. Announces Planned Merger with Ayrmid Ltd. to Strengthen Company for the Future
prnewswire.com · Nov 2
Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
prnewswire.com · Oct 1
Reviewing Alpha Cognition (NASDAQ:ACOG) & Karyopharm Therapeutics (NASDAQ:KPTI)
defenseworld.net · Sep 30
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
prnewswire.com · Sep 1
Karyopharm Submits Supplemental New Drug Application to the FDA for XPOVIO® (selinexor) Plus Ruxolitinib for Patients with Myelofibrosis
gurufocus.com · Aug 31
Karyopharm Submits Supplemental New Drug Application to the FDA for XPOVIO® (selinexor) Plus Ruxolitinib for Patients with Myelofibrosis
prnewswire.com · Aug 31
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.